Market Overview:
The global OAB treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of overactive bladder (OAB) and rising demand for better treatment options. The anticholinergics segment is expected to dominate the market during the forecast period, owing to their high efficacy and safety profile. However, mirabegron is expected to grow at a higher CAGR due to its better tolerability profile as compared with anticholinergics. By application, idiopathic OAB is estimated to account for the majority of the market share in 2018 and neurogenic OAB is projectedto bethe fastest-growing segment duringthe forecast period.
Product Definition:
OAB Treatment is the medical treatment of overactive bladder. Treatment options include behavioral therapies, medications, and surgery. Behavioral therapies include pelvic floor muscle exercises (Kegel exercises), bladder training, and dietary changes. Medications include anticholinergics, beta-3 agonists, mirabegron, and solifenacin succinate. Surgery includes procedures to help increase the storage capacity of the bladder or to reduce urinary spasms.
Anticholinergics:
Anticholinergic drugs are used to treat Oropharyngeal (ORPH) syndrome. It is a group of conditions that occur due to the excessive production of anticholinergic substances in the body. These substances act upon the nerve responsible for stimulating muscle contractions and relaxing glandular tissues, which ultimately leads to blockage of saliva, gastric acid and stomach muscles, and other digestive juices from entering into the upper gastrointestinal tract.
Mirabegron:
Mirabegron is a peripherally restricted drug that reduces the frequency of contractions in the bladder. It is used to treat overactive bladder (OAB) and urinary incontinence (UI) and has been approved by Health Canada for this purpose. The drug was first approved in Japan in 2007, however, it received approval from European Union, U.S., and Canadian governments only after 2010 due to expiry of patent exclusivities related to the product.
Application Insights:
Based on application, the global market is segmented into idiopathic overactive bladder (OAB) and neurogenic OAB. The former was estimated to be the largest segment in 2017 owing to a high prevalence of OAB among women above 50 years of age. This condition often goes undiagnosed due to lack of awareness about it. It also affects people who have had spinal surgery or trauma, or who are obese or have diabetes mellitus.
The symptoms include frequent urination at night time and during sleep as well as daytime panting and increased urgency to urinate with no significant increase in urinary flow rates. In addition, pain/strain while passing urine and burning sensation when trying to pass urine may also occur along with other symptoms such as dry mouth, constipation etc.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of OAB are some factors responsible for its dominance. In addition, the availability of highly advanced healthcare infrastructure is expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness rapid growth over the forecast period owing to rising geriatric population and awareness about bladder management disorders in this region. Moreover, improving healthcare facilities and growing medical tourism are also contributing toward regional market development. Increasing incidence of neurogenic overactive bladder due to increased exposure to environmental triggers such as cigarette smoking may also boost demand for MOCs in this region during the estimated time frame (2018-2030).
Growth Factors:
- Increasing prevalence of OAB
- Growing awareness about the available treatment options for OAB
- Rising demand for minimally invasive procedures
- Technological advancements in the field of OAB treatment
- Growing number of clinical studies on new treatments for OAB
Scope Of The Report
Report Attributes
Report Details
Report Title
OAB Treatment Market Research Report
By Type
Anticholinergics, Mirabegron, Botox
By Application
Idiopathic Overactive Bladder, Neurogenic Overactive Bladder
By Companies
Astellas Pharma, Allergan, Pfizer, Teva (Activas), Johnson & Johnson
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
222
Number of Tables & Figures
156
Customization Available
Yes, the report can be customized as per your need.
Global OAB Treatment Market Report Segments:
The global OAB Treatment market is segmented on the basis of:
Types
Anticholinergics, Mirabegron, Botox
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Idiopathic Overactive Bladder, Neurogenic Overactive Bladder
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma
- Allergan
- Pfizer
- Teva (Activas)
- Johnson & Johnson
Highlights of The OAB Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anticholinergics
- Mirabegron
- Botox
- By Application:
- Idiopathic Overactive Bladder
- Neurogenic Overactive Bladder
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the OAB Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
OAB Treatment is a medical procedure that helps relieve the symptoms of OAB, such as difficulty breathing. This treatment may include medications, surgery, or a combination of both.
Some of the major players in the oab treatment market are Astellas Pharma, Allergan, Pfizer, Teva (Activas), Johnson & Johnson.
The oab treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 OAB Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 OAB Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 OAB Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the OAB Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global OAB Treatment Market Size & Forecast, 2018-2028
4.5.1 OAB Treatment Market Size and Y-o-Y Growth
4.5.2 OAB Treatment Market Absolute $ Opportunity
Chapter 5 Global OAB Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 OAB Treatment Market Size Forecast by Type
5.2.1 Anticholinergics
5.2.2 Mirabegron
5.2.3 Botox
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global OAB Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 OAB Treatment Market Size Forecast by Applications
6.2.1 Idiopathic Overactive Bladder
6.2.2 Neurogenic Overactive Bladder
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global OAB Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 OAB Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America OAB Treatment Analysis and Forecast
9.1 Introduction
9.2 North America OAB Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America OAB Treatment Market Size Forecast by Type
9.6.1 Anticholinergics
9.6.2 Mirabegron
9.6.3 Botox
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America OAB Treatment Market Size Forecast by Applications
9.10.1 Idiopathic Overactive Bladder
9.10.2 Neurogenic Overactive Bladder
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe OAB Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe OAB Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe OAB Treatment Market Size Forecast by Type
10.6.1 Anticholinergics
10.6.2 Mirabegron
10.6.3 Botox
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe OAB Treatment Market Size Forecast by Applications
10.10.1 Idiopathic Overactive Bladder
10.10.2 Neurogenic Overactive Bladder
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific OAB Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific OAB Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific OAB Treatment Market Size Forecast by Type
11.6.1 Anticholinergics
11.6.2 Mirabegron
11.6.3 Botox
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific OAB Treatment Market Size Forecast by Applications
11.10.1 Idiopathic Overactive Bladder
11.10.2 Neurogenic Overactive Bladder
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America OAB Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America OAB Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America OAB Treatment Market Size Forecast by Type
12.6.1 Anticholinergics
12.6.2 Mirabegron
12.6.3 Botox
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America OAB Treatment Market Size Forecast by Applications
12.10.1 Idiopathic Overactive Bladder
12.10.2 Neurogenic Overactive Bladder
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) OAB Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) OAB Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) OAB Treatment Market Size Forecast by Type
13.6.1 Anticholinergics
13.6.2 Mirabegron
13.6.3 Botox
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) OAB Treatment Market Size Forecast by Applications
13.10.1 Idiopathic Overactive Bladder
13.10.2 Neurogenic Overactive Bladder
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 OAB Treatment Market: Competitive Dashboard
14.2 Global OAB Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas Pharma
14.3.2 Allergan
14.3.3 Pfizer
14.3.4 Teva (Activas)
14.3.5 Johnson & Johnson
